Alpha1 Blocker — Competitive Intelligence Brief

Alpha1 Blocker (Alpha1 Blocker) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-1 adrenergic receptor antagonist. Area: Cardiovascular, Urology.

marketed Alpha-1 adrenergic receptor antagonist Alpha-1 adrenergic receptor Cardiovascular, Urology Small molecule

Target snapshot

Alpha1 Blocker (Alpha1 Blocker) — Eli Lilly and Company. Alpha-1 blockers inhibit alpha-1 adrenergic receptors on vascular smooth muscle and the prostate, causing vasodilation and reduced urinary obstruction.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Alpha1 Blocker TARGET	Alpha1 Blocker	Eli Lilly and Company	marketed	Alpha-1 adrenergic receptor antagonist	Alpha-1 adrenergic receptor
norepinephrine+vasopressin	norepinephrine+vasopressin	Peking Union Medical College Hospital	marketed	Vasopressor combination	Alpha-1 adrenergic receptor, beta-1 adrenergic receptor, vasopressin V1 receptor
Doxazosin mysylate GITS	Doxazosin mysylate GITS	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	marketed	Alpha-1 adrenergic receptor antagonist	Alpha-1 adrenergic receptor
labetalol intravenous	labetalol intravenous	Haseki Training and Research Hospital	marketed	Alpha-beta adrenergic antagonist	Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor
Norepinephrine (Levophed)	Norepinephrine (Levophed)	University of Louisville	marketed	Catecholamine; sympathomimetic amine	Alpha-1 adrenergic receptor; alpha-2 adrenergic receptor; beta-1 adrenergic receptor
norepinephrine versus midodrine & octreotide	norepinephrine versus midodrine & octreotide	National Hepatology & Tropical Medicine Research Institute	marketed	Sympathomimetic amine / Alpha-1 adrenergic agonist / Somatostatin analog	Alpha-1 adrenergic receptor / Beta-1 adrenergic receptor / Somatostatin receptor
ephedrine and phenylephrine	ephedrine and phenylephrine	University Hospital, Clermont-Ferrand	marketed	Sympathomimetic amine / Adrenergic agonist	Alpha-1 adrenergic receptor, beta-1 adrenergic receptor, beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-1 adrenergic receptor antagonist class)

1. Brian J Lipworth · 1 drug in this class
2. CHU de Quebec-Universite Laval · 1 drug in this class
3. Eli Lilly and Company · 1 drug in this class
4. Haffkine Bio-Pharmaceutical Corporation Ltd. · 1 drug in this class
5. Hospital Authority, Hong Kong · 1 drug in this class
6. Japan Heart Foundation · 1 drug in this class
7. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
8. San Francisco Veterans Affairs Medical Center · 1 drug in this class
9. Sanofi · 1 drug in this class
10. Shanghai Huilun Pharmaceutical Co., Ltd. · 1 drug in this class